Smith & Nephew (LON:SN) Earns Overweight Rating from JPMorgan Chase & Co.

Smith & Nephew (LON:SN)‘s stock had its “overweight” rating reaffirmed by equities researchers at JPMorgan Chase & Co. in a research note issued on Tuesday, MarketBeat.com reports. They presently have a GBX 1,180 ($14.44) price objective on the stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 20.65% from the stock’s previous close.

Smith & Nephew Price Performance

SN stock opened at GBX 978 ($11.97) on Tuesday. The firm has a 50-day moving average of GBX 979.36 and a 200-day moving average of GBX 1,073.85. The company has a quick ratio of 0.84, a current ratio of 2.51 and a debt-to-equity ratio of 70.22. The firm has a market cap of £8.53 billion, a price-to-earnings ratio of 3,622.22, a P/E/G ratio of 0.46 and a beta of 0.62.

Insider Buying and Selling

In other Smith & Nephew news, insider Deepak Nath sold 34,033 shares of Smith & Nephew stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of GBX 981 ($12.01), for a total transaction of £333,863.73 ($408,645.94). Also, insider John Rogers acquired 71,920 shares of Smith & Nephew stock in a transaction on Thursday, December 19th. The stock was purchased at an average price of GBX 972 ($11.90) per share, with a total value of £699,062.40 ($855,645.53). 0.19% of the stock is owned by company insiders.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.